These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 3177254)

  • 1. Pilot study of adriamycin and amsacrine (m-AMSA) in patients with advanced breast cancer.
    Chang AY; Solan A; Kaplan BH; Vogl SE; Camacho FJ; Taylor SG
    Am J Clin Oncol; 1988 Oct; 11(5):535-7. PubMed ID: 3177254
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II study of AMSA alone and in combination with DTIC in patients with metastatic melanoma.
    Polyzos A; Legha SS; Burgess AM; Benjamin RS; Bodey GP
    Invest New Drugs; 1988 Apr; 6(1):57-61. PubMed ID: 3410667
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II study of AMSA and doxorubicin to treat metastatic breast cancer.
    Casimir MT; Buzdar AU; Blumenschein GR; Hortobagyi GN; Bodey GP
    Oncology; 1986; 43(4):205-7. PubMed ID: 3755230
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effective reinduction therapy for childhood acute nonlymphoid leukemia using simultaneous continuous infusions of teniposide and amsacrine.
    Mirro J; Kalwinsky DK; Grier HE; Santana VM; Mason C; Murphy SB; Dahl GV
    Cancer Chemother Pharmacol; 1989; 24(2):123-7. PubMed ID: 2731312
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A dose-seeking trial of edatrexate in combination with vinblastine, adriamycin, cisplatin, and filgrastim (EVAC/G-CSF) in patients with advanced malignancies: promising antineoplastic activity against non-small cell lung carcinomas.
    Colón-Otero G; Marschke R; Camoriano JK; Sorensen JM; Sloan JA; Richardson RL
    Cancer J Sci Am; 1997; 3(5):297-302. PubMed ID: 9327154
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Amsacrine [4'-(9-acridinylamino)-methanesulfon-m-anisidide] (m-AMSA) and 5-azacytidine (AZA) for remission reinduction in patients with relapsed adult acute nonlymphocytic leukemia. An ECOG pilot study. Eastern Cooperative Oncology Group.
    Kahn SB; Spiers A; Knospe WH; Soojian M; Glick JH
    Am J Clin Oncol; 1987 Feb; 10(1):78-81. PubMed ID: 2435142
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-dose infusional doxorubicin and cyclophosphamide: a feasibility study of tandem high-dose chemotherapy cycles without stem cell support.
    Morgan RJ; Doroshow JH; Venkataraman K; Chang K; Raschko J; Somlo G; Leong L; Tetef M; Shibata S; Hamasaki V; Margolin K; Forman S; Akman S; Coluzzi P; Ahn C; Weiss L; Gadgil U; Harrison J
    Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2337-45. PubMed ID: 9815632
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Docetaxel/doxorubicin/cyclophosphamide in the treatment of metastatic breast cancer.
    Nabholtz JM; Smylie M; Mackey JR; Noel D; Paterson AH; al-Tweigeri T; Au D; Sansregret E; Delorme F; Riva A
    Oncology (Williston Park); 1997 Aug; 11(8 Suppl 8):37-41. PubMed ID: 9364541
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sequential adjuvant therapy with doxorubicin/paclitaxel/cyclophosphamide for resectable breast cancer involving four or more axillary nodes.
    Hudis CA; Seidman AD; Baselga J; Raptis G; Lebwohl D; Gilewski T; Currie V; Moynahan ME; Sklarin N; Fennelly D
    Semin Oncol; 1995 Dec; 22(6 Suppl 15):18-23. PubMed ID: 8643965
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intermediate doses of cyclophosphamide alone or following adriamycin in advanced breast cancer. A pilot study.
    Zambetti M; Terenziani M; Bartoli C; Valagussa P; Piotti P; Ferranti C; Bonadonna G
    Am J Clin Oncol; 1996 Feb; 19(1):82-6. PubMed ID: 8554043
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Effects of DAC (doxifluridine, adriamycin, cyclophosphamide) chemotherapy in advanced breast cancer patients].
    Tashiro H; Takahashi I; Yamamura S; Ishikawa T; Yanaga K; Wakasugi K; Matsusaka T; Kume K
    Gan To Kagaku Ryoho; 1999 May; 26(6):775-9. PubMed ID: 10410146
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase II evaluation of m-AMSA, 4'-(9-acridinylamino) methanesulfon-m-anisidide, in patients with breast cancer.
    Currie VE; Howard J; Wittes R
    Cancer Clin Trials; 1981; 4(3):249-51. PubMed ID: 6895189
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II trial of cyclophosphamide, doxorubicin, and cisplatin (CAP) versus amsacrine in patients with transitional cell carcinoma of the urinary bladder: a Southwest Oncology Group study.
    Al-Sarraf M; Frank J; Smith JA; O'Bryan RM; Costanzi JJ; Stephens RL; Caraveo J; Crawford ED
    Cancer Treat Rep; 1985 Feb; 69(2):189-94. PubMed ID: 2578880
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of metastatic breast cancer by navelbine, mitoxantrone and continuous infusion 5-fluorouracil (FMN regimen): results of a pilot study.
    Azim HA
    J Infus Chemother; 1996; 6(2):102-6. PubMed ID: 8809659
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study.
    Gianni L; Munzone E; Capri G; Fulfaro F; Tarenzi E; Villani F; Spreafico C; Laffranchi A; Caraceni A; Martini C
    J Clin Oncol; 1995 Nov; 13(11):2688-99. PubMed ID: 7595726
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase I/II study of sequential doxorubicin and paclitaxel in the treatment of advanced breast cancer.
    Amadori D; Frassineti GL; Zoli W; Milandri C; Tienghi A; Ravaioli A; Gentile A; Salzano E
    Semin Oncol; 1996 Oct; 23(5 Suppl 11):16-22. PubMed ID: 8893894
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase II study of AMSA in head and neck cancer.
    Crivellari D; Tirelli U; Frustaci S; Veronesi A; Galligioni E; Tumolo S; Grigoletto E
    Am J Clin Oncol; 1987 Feb; 10(1):23-5. PubMed ID: 3825990
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase II study of intravenous navelbine and doxorubicin combination in previously untreated advanced breast carcinoma.
    Pawlicki M; Rolski J; Zaluski J; Siedlecki P; Ramlau C; Tomzak P
    Oncologist; 2002; 7(3):205-9. PubMed ID: 12065792
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multicenter randomized trial comparing sequential with concomitant administration of doxorubicin and docetaxel as first-line treatment of metastatic breast cancer: a Spanish Breast Cancer Research Group (GEICAM-9903) phase III study.
    Alba E; Martín M; Ramos M; Adrover E; Balil A; Jara C; Barnadas A; Fernández-Aramburo A; Sánchez-Rovira P; Amenedo M; Casado A;
    J Clin Oncol; 2004 Jul; 22(13):2587-93. PubMed ID: 15226326
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intermediate-dose Ara-C/m-AMSA for remission induction and high-dose Ara-C/m-AMSA for intensive consolidation in relapsed and refractory adult acute myelogenous leukemia (AML).
    Jehn U; Heinemann V; Wilmanns W
    Anticancer Res; 1989; 9(1):119-24. PubMed ID: 2705739
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.